Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th CongressGlobeNewsWire • 09/23/21
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/21
Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/21
Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease CandidateBenzinga • 07/14/21
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common StockGlobeNewsWire • 07/14/21
Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The BeginningSeeking Alpha • 07/13/21
Celldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatmentsMarket Watch • 07/12/21
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021GlobeNewsWire • 07/09/21
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual MeetingGlobeNewsWire • 06/04/21
Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021GlobeNewsWire • 06/01/21
Celldex Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/06/21
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021GlobeNewsWire • 04/12/21